|
INVION LTD : Invion announces initiation of phase II asthma study
4-traders Invion Limited (ASX:IVX), a clinical-stage drug development company targeting chronic inflammation, today announced the initiation of "NIMA", a phase II clinical trial that is funded by the US National Institute of Allergy and Infectious Diseases … |
View full post on asthma – Google News